À retenir
A narrative review found high diagnostic accuracy for arrhythmia detection and promising results in heart failure monitoring from AI-enabled wearables, particularly FDA- or CE-approved devices. Most studies were small, short-term and in controlled settings, and the review reports no pooled numbers.
Study design
Article de recherche
Reading basis
Published abstract
Reading focus
Design & applicability
Cette explication éditoriale existe en anglais, chinois simplifié et chinois traditionnel. Cette interface affiche la lecture en anglais.
Question de recherche
AI-integrated wearable devices promise real-time cardiovascular monitoring and earlier detection, but the quality and clinical usefulness of the evidence vary. The authors reviewed what is known about AI-enabled wearables for heart disease, and where the gaps are.
Population et méthode
Narrative review of peer-reviewed original studies, clinical trials, reviews and regulatory documents published in English from January 2013 to June 2025, found with a structured Boolean search. Selection prioritised randomised trials, prospective observational studies and real-world implementation reports with a clear regulatory context. Studies were analysed narratively for device classification, physiological parameters, AI techniques, clinical validation and patient engagement. The abstract does not name the databases or give the number of studies.
Résultats
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Evidence shows high diagnostic accuracy for arrhythmia detection and promising outcomes in heart failure monitoring, especially for devices approved by the Food and Drug Administration (FDA) or with Conformité Européenne (CE) marking.
- 2Most studies were small, short-term and conducted in controlled settings, which limits how far results generalise.
- 3Gaps include underrepresentation of diverse populations, lack of interoperability with electronic health records, limited AI explainability and incomplete cost-effectiveness evaluation.
- 4Patient engagement was inconsistently addressed, with most studies reporting only basic usability or satisfaction.
Limites et incertitude
- 1A narrative review with no stated number of studies and no pooled estimates cannot show how accurate any device is on average.
- 2Accuracy figures come mostly from small, controlled settings, so real-world false alarms and missed events are not captured.
- 3Authors prioritised certain study designs, so the selection may favour favourable evidence; the abstract does not describe quality appraisal.
- 4This reading is based on the abstract only.
Mise en perspective
Smartwatch and patch rhythm alerts can be a useful prompt to get checked, but the review does not show they improve outcomes in routine life. A warning or a normal reading should lead to a conversation with your clinician, not a self-diagnosis.
Vos données
Heart rate, irregular-rhythm notifications and ECG-style recordings from your watch are the consumer cousins of the devices reviewed. Use the same device and wear it as directed, save any alert recordings to show your clinician, and treat trends as context, not proof.
Comprendre ce type de preuve
The index does not establish a precise design. Read the methods before making causal claims; check population, comparator, outcomes and uncertainty in the source.
Résumé structuré des auteurs English
Le résumé original en anglais est reproduit avec attribution sous la licence ouverte indiquée. Il s’agit d’une source, pas d’une interprétation MoveVitals. L’analyse préparée figure ci-dessus ; vérifiez les conclusions importantes dans la source.
Background
AI-integrated wearable devices (WDs) offer real-time cardiovascular disease (CVD) monitoring with the potential to improve early detection and patient-centred care. However, the breadth, quality, and clinical applicability of supporting evidence remain variable.
Methods
A narrative review was conducted of peer-reviewed original studies, clinical trials, reviews, and regulatory documents published in English from January 2013 to June 2025. A structured Boolean search identified literature on AI-enabled WDs for cardiovascular monitoring. Selection criteria prioritised randomised trials, prospective observational studies, and real-world implementation reports with a clear regulatory context. Studies were narratively analysed for device classification, physiologic parameters measured, AI techniques, clinical validation outcomes, and evidence of patient engagement.
Results
Evidence demonstrates high diagnostic accuracy for arrhythmia detection and promising outcomes in heart failure monitoring, particularly with Food and Drug Administration or Conformité Européenne-approved devices. Nonetheless, most studies were small, short-term, and conducted in controlled settings, limiting generalisability. Key gaps include underrepresentation of diverse populations, lack of interoperability with electronic health records, limited AI explainability, and incomplete cost-effectiveness evaluation. Patient engagement was inconsistently addressed, with most reporting only basic usability or satisfaction measures rather than co-design or adherence optimisation strategies.
Conclusion
AI-integrated WDs show considerable promise in enhancing CVD detection and management but require large-scale pragmatic trials, standardised interoperability protocols, transparent AI model interpretability, and structured patient involvement. Addressing these gaps will be essential for equitable, scalable, and clinically integrated adoption.
Sources et attribution
Wearable Devices and AI-Driven Remote Monitoring in Cardiovascular Medicine: A Narrative Review.
Gaoudam N, Sakhamudi SK, Kamal B, Addla N, Reddy EP, Ambala M, Lavanya K, Palaparthi EC, Bhattam A, Periasamy P, Sayana SB, Medabala T.
Cureus · 2025-08-16
DOI: 10.7759/cureus.90208 ↗PubMed · 40964568 ↗Europe PMC · Licence indiquée: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interprétation éditoriale MoveVitals · contenu éducatif · aucune évaluation clinique individuelle enregistrée
Sources vérifiées 2026-11-01
Guides pratiques
À lire ensemble
Activity–stroke and heart attack curves differ by accelerometer processing method
Among 90,237 UK Biobank adults free of cardiovascular disease at baseline, followed until December 2022 for 1,298 strokes and 2,031 myocardial infarctions, the shape of the link between moderate-vigorous physical activity (MVPA) and each outcome depended on how the accelerometer data were processed. For stroke, hazard fell in a straight line only with the machine-learning metric; for myocardial infarction, two metrics gave a curved decline and activity counts a straight one. The abstract gives no hazard ratios, so it shows that methods disagree, not which one is right, and the findings are observational associations.
Preventive Medicine
Smartwatch data as forensic evidence: heart rate is best validated, the rest uneven
A systematic review and meta-analysis of studies on smartwatches from four major brands, framed around digital forensics, found that heart rate was both the most studied and the most accurate measure. Step count, distance, energy expenditure, activity classification and sleep were less consistently validated, and results varied by brand, protocol and reporting. The abstract gives no pooled numbers, and most studies were run in healthy people in laboratories, so it cannot say how a particular watch performs for a particular person in daily life.
Forensic Science International
Activity trackers: about 1,800 more steps a day, but small effects on other outcomes
An umbrella review of 39 systematic reviews and meta-analyses, covering 163,992 participants, found that activity trackers were associated with more physical activity (SMD 0.3–0.6), equating to about 1,800 extra steps and 40 minutes more walking per day, and with a bodyweight reduction of about 1 kg. Effects on blood pressure, cholesterol, glycosylated haemoglobin, quality of life and pain were typically small and often non-significant. The abstract does not say what else came with the trackers in these programs or how much the reviews overlap, so the gains cannot be credited to the device alone.
The Lancet Digital Health
Seven sleep trackers: good at spotting sleep, weak on wake and sleep stages
In a sleep laboratory, 34 healthy young adults wore a subset of seven consumer sleep trackers for three nights. Against polysomnography every device detected sleep very well (sensitivity 0.93 or higher) but caught wake poorly (specificity 0.18–0.54), and five of the seven matched or beat research actigraphy (specificity 0.39). Sleep-stage estimates were inconsistent, and the participants were healthy adults aged 18 to 35 in a fixed 8-hour bed window, with each device tested in only 11 to 20 of them, so the results say little about people with sleep problems.
Sleep

